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ABSTRACT 
One of the mechanisms for generation of tolerance involves immature dendritic cells 
(DCs) and a subpopulation of regulatory CD4+ CD25+ T lymphocytes (TREG). The 
purpose of this work was to analyze how Cyclosporine A (CsA), a widely used 
immunosuppressive drug, may affect TREG proliferation. Purified and activated murine 
DCs obtained from bone marrow precursors differentiated with rGMCSF were co-
cultured with purified CFSE-labeled TREG from OTII mice, and their phenotype and 
proliferation analyzed by flow cytometry. Our data indicate that DCs differentiated in 
the presence of CsA show an altered phenotype, with a lower expression of MHC-II and 
a lower activating capacity. Additionally, these CsA-treated DCs show decreased 
production of IL-2 and IL-12 and increased IL-10 secretion when stimulated with LPS, 
indicating an effect on the polarization of the immune response. Interestingly, CsA-
treated DCs show an anti-tolerogenic effect since they reduce the proliferation of TREG 
cells from 72 to 47%. Further inhibition to a 24% of TREG proliferation was obtained as 
a direct effect of CsA on TREG. In conclusion, the anti-tolerogenic effect of CsA should 
be considered in the planning of immunosuppression in the context of clinical 
transplantation. 





Dendritic cells (DCs) represent a heterogeneous population of uniquely well-equipped 
antigen-presenting cells that link innate and adaptive immunity and initiate and 
regulate immune response (1). Additionally, DCs control immunity through their ability 
to induce antigen-specific unresponsiveness of lymphocytes in primary and secondary 
lymphoid tissues. It has also been shown that subcutaneous administration of 
autologous immature DCs induces antigen-specific T cell tolerance in human volunteers 
(2). This, as well as results from several other groups, have led to the notion that a 
state of immune tolerance can be elicited by immature DCs (3). 
The initial demonstration by Nishizuka and Sakakura (4), later confirmed by Sakaguchi 
et al. (5) that a subpopulation of T lymphocytes actively down-regulate immune 
responses, challenged traditional immunology concepts. Sakaguchi et al. demonstrated 
that mice depleted of CD25 expressing cells developed various autoimmune diseases, 
and that this phenomenon could be reversed by reconstituting the animals with this 
same cell population (6). Thus, these regulatory T cells (TREG) were able to inhibit the 
immune reactivity of T cell clones specific for self-antigens. 
Cyclosporin A (CsA), an immunosuppressive agent widely used in a variety of 
conditions such as organ transplant and autoimmune diseases, acts by blocking the 
transcription of the gene encoding IL-2. It has been shown that in the autoimmune 
disease-prone athymic nu/nu mice, autoimmunity can be prevented by the transfer of 
thymocytes suspensions obtained from normal nu/+ mice, but not by thymocytes from 
CsA-treated nu/+ mice (7). Thus, CsA appears to interfere selectively with the thymic 
production of certain T cells regulating the activity of self-reactive (autoimmune) T 
cells, allowing the latter to expand and cause autoimmune disease. It has been also 
been shown that CsA exerts immunomodulatory effects on human DCs, inhibiting IL-12 
production and Thl skewing (8). Moreover, results from our laboratory, as well as 
others, indicate that CsA also blocks IL-2 secretion by murine bone marrow DC (BMDC) 
(9). These results are particularly relevant if one considers recent results by Furtado et 
al. (10) showing that in a model of spontaneous experimental autoimmune 
encephalomyelitis, IL-2 signaling is an absolute requirement for TREG cells to exert their 
autoimmune protective function. Recently, Kawai M et al. (11) showed that in vivo 
administration of CsA in high doses inhibits the proliferation of CD4+ CD25+ TREG cells, 
while at low doses it favors TREG proliferation. In spite of these apparently contradictory 
effects of CsA on TREG cells function, to our knowledge there is no report addressing the 
question as to whether CsA inhibits TREG activity by acting directly upon these cells or 
indirectly owing to its action on DCs. 
Here we report that dendritic cells, generated from bone marrow precursors in the 
presence of CsA in a concentration of 750 ng/mL (representative of the standard 
Cmax, i.e. the maximal CsA blood concentration used in maintenance 
immunosuppression in clinical transplantation), reduced Treg proliferation. This 
inhibitory effect of CsA was enhanced when the drug was also present during co-
cultures of DCs with T cells. In addition, we report that bone marrow-derived DCs 
generated in the presence of CsA show a more immature phenotype, a lower IL-12 and 
IL-2 secretion post-activation and an enhanced IL-10 production compared to DCs 
generated in the absence of the drug. These results show that CsA produces an 
ambivalent effect in DCs: on the one hand it sustains an immature potentially 
tolerogenic DC phenotype, while on the other, it actually reduces TREG proliferation, 
probably due to changes on the cytokine pattern secretion. 
MATERIALS AND METHODS 
Mice: C57BL/6 H-2b (B6) mice were purchased from Jackson Laboratories (Bar Harbor, 
ME) and OT-II CD4+ transgenic mice were obtained from The Scripps Laboratories 
(San Diego, CA). These TCR transgenic mice recognize a peptide derived from OVA 
(positions 323-339) in the context of I-Ab. Mice were used at 8 to 12 weeks of age and 
housed in a specific pathogen-free facility. 
Bone Marrow Dendritic Cells: Bone marrow DCs were generated as described 
previously with minor modifications (9). Briefly, bone marrow cells were removed from 
the femurs and tibias of B6 mice and depleted of erythrocytes by hypotonic lysis. The 
cells (1 x 106) were cultured for 5 days in 1 mL of RPMI 1640, supplemented with 10% 
v/v FBS, murine recombinant GM-CSF (10 ng/mL) (Pharmingen, USA) in the presence 
or not of CsA (750 ng/mL) (Sigma, St Louis Missouri, USA), at 37°C and 5% C02. At 
days 2 and 4, 75% of supernatant was replaced with 1 mL of fresh media (with rGM-
CSF ± CsA). At day 5 cells were harvested and incubated with bead-conjugated anti-
CDllc monoclonal antibody (anti-CDllc kit, Miltenyi Biotec, USA) for 15 min at 4°C DCs 
were purified with magnetic columns by positive selection according to the 
manufacturer's instructions. The purity and phenotype of the DC was analyzed by flow 
cytometry. 
DC activation: CDllc+ DC purified on day 5, were re-plated at 1 x 106 cells/ml in 250 ml 
of RPMI 1640 supplemented with 10% FBS and rGM-CSF ± CsA (750 ng/ mL) and 
activated with 100 ng/ml LPS (Sigma, St. Louis, MO, USA) as indicated. After 4 h of 
incubation, supernatants were harvested and tested for mouse IL-12p70, IL-10 and IL-
2 using enzyme-linked immunosorbent assay (ELISA) kits (BD PharMingen) according 
to the manufacturer's instructions. 
CD4+ regulatory T cells (TREG): CD4+ regulatory T cells were isolated from the spleen 
of OT-II mice using an immunomagnetic isolation kit (Miltenyi Biotec, USA). Spleen 
cells were treated with a cocktail of monoclonal antibodies that deplete all the cells, 
except CD4+ T cells then CD4+CD25+ regulatory T are isolated by selecting cells for 
high expression of the CD25 marker by immunomagnetic selection. The phenotype of 
the purified cells was confirmed by flow cytometry for the expression of intracellular 
Foxp3. Treg cells were resuspended in 500 mL of RPMI 1640 media without serum and 
stained with CFSE (5 mM) (Molecular Probes, Eugene Oregon, USA). After 10 min of 
incubation at 37°C, the cells were washed twice with RPMI 1640 supplemented with 
10% v/v FBS. 
Co-cultures: DC (1.5xl04) were resuspended in 150 |iL of RPMI 1640 supplemented 
with 10% v/v FBS ± CsA and activated for 4 h at 37°C and 5% C02 with 100 ng/mL of 
LPS in 96-well culture plates. Following this, OVA (0.2 mg/mL) was added to the wells, 
and 30 min later TREG cells resuspended in 150 |iL of RPMI 1640 supplemented with 
10% v/v FBS, were added to the cultures. Co-cultures were left at 37°C and 5% C02, 
and at day 5 cells were harvested for flow cytometry analysis. 
Flow Cytometry: The DC phenotype was studied using fluorochrome-conjugated 
antibodies (anti-CDllc-PE (HL3 clone), anti-I-A/I-E-FITC (2G9 clone), anti-CD80-FITC 
(16-10A1 clone), anti-CD86 FITC (GL1 clone), anti-CD83 APC (Michel-19 clone) and 
anti-CD40 APC (1C10 clone). To study the TREG phenotype and proliferation, cells were 
harvested at day 5 of co-culture, resuspended in RPMI plus 2% FCS, stained with the 
relevant mAbs for 20 min at 4°C, washed, and analyzed on a FACScan (BD 
Biosciences, Mountain View, CA) using the Cellquest program. The following mAbs 
from PharMingen were used: anti-CD4-PerCP and anti-CD25-PE. CFSE dilution was 
analyzed together with the expression of these markers. 
RESULTS 
Bone marrow-derived dendritic cells generated in the presence of CsA decrease TREG 
proliferation 
Considering that TREG function has been shown to depend upon IL-2 and that CsA 
inhibits the secretion of this cytokine by T cells and DCs (9), we sought to determine 
the influence that DCs generated in the presence of CsA had on TREG proliferation. In 
one set of experiments, CFSE-labeled TREG isolated from OTII transgenic mice were co-
cultured with peptide-pulsed BMDC in the absence of CsA. Under this condition, TREG 
showed a proliferation of 71.9% (Fig. 1A). On the other hand, when CFSE-labeled TREG 
were co-cultured with peptide-pulsed BMDC differentiated in the presence of CsA, TREG 
proliferation decreased to a 47.4% (Fig 1D). Since in these experiments no CsA was 
present at the time TREG were added, the effect of the drug on Treg proliferation could 
only be attributed to its prior interaction with DCs during their differentiation. 
Additionally, when CsA was also present during the period of co-culture of the CFSE-
labeled transgenic Treg with the peptide-loaded BMDC, proliferation was further 
diminished to values close to 25%, irrespective if the BMDC were generated in the 
presence (Fig. 1B) or in the absence of CsA (Fig. 1C). Moreover, when DCs generated 
in the presence of CsA were pre-activated for 4h with LPS and then peptide-pulsed and 
co-cultured with TREG for the time of the experiment, TREG cells did not show any 
proliferation (last row Fig. 1) indicating that activated BMDC do not sustain 
proliferation of TREG. 
 Phenotype of BMDC differentiated with CsA 
To examine the effect of CsA on BMDC differentiation, bone marrow precursors were 
cultured in the presence of GM-CSF ± CsA (750 ng/mL). After 5 days of culture, the 
resulting BMDC were purified through magnetic column as indicated in Material and 
Methods and stained to analyze by flow cytometry on the CDllc+ DC, the surface 
expression of several maturation markers, such as MHC-II, CD86, CD83, CD40 and 
CD80. As a representative result Figure 2 shows that although no differences could be 
detected with regard to the percentage of cells positive for these markers, there is a 
marked reduction in the mean fluorescence intensity (MFI) for MHC-II on DC 
differentiated in the presence of CsA, indicating that this drug decreases the antigen 
presenting capacity of these cells, while it does not affect the expression of other co-
stimulatory molecules. However, when CsA-treated BMDCs were activated with LPS for 
4h, the most remarkable effect was on the expression of CD86 marker, since there was 
almost no increase in the percentage of CD86+ cells, contrary to what happens with all 
other markers (data not shown), suggesting that BMDC differentiated in the presence 
of CsA are in someway more immature DCs. 
CsA inhibits IL-2 and IL-12 while enhancing IL-10 secretion on BMDC 
In view of the impact of CsA on DC maturation, we decided to analyze the effect of CsA 
on the cytokine secretion pattern of DC in response to an inflammatory stimulus. 
BMDC differentiated in the presence or absence of CsA were stimulated with LPS (100 
ng/mL) for 4 hours and the supernatants harvested for cytokine analysis. The results 
indicate that DCs differentiated with GM-CSF alone secrete IL-2, IL-12 and IL-10 in 
response to LPS, while DCs differentiated in the presence of GM-CSF plus 750 ng/mL of 
CsA, secreted significantly less IL-2 and IL-12, while IL-10 secretion was slightly 
enhanced as compared to non-treated DCs, suggesting that DC-treated with the drug 
may differentially influence lymphocyte polarization (Fig. 3). 
DISCUSSION 
TREG are a subset of T cells that regulate the immune response to self and non-self 
antigens and may prevent or down regulate the effector arm of the immune response. 
For example, in solid organ and tissue transplantation, co-transfer of TREG into T cell 
deficient mice along with CD4+CD25+ effector T cells block the ability of these effector 
T cells to reject allogeneic skin grafts (13, 14, 15) indicating that TREG play a role in 
inhibiting transplant rejection and achieving tolerance in animal models. 
The best-characterized TREG have been isolated by their constitutive surface expression 
of CD4 and CD25, the high affinity alpha chain of the IL-2 receptor. IL-2 seems to be 
necessary for the proliferation of TREG cells as suggested by studies showing that TREG 
are absent in IL-2 deficient mice (16). It has been shown that CsA inhibits the 
proliferation of TREG in vivo (11) a phenomena that was envisaged in the early 80's 
(17). This effect may happen by a direct action of CsA on the Treg or indirectly through 
an effect upon the stimulatory and antigen presenting DC. Recent reports indicate that 
DC produce IL-2 (18) and that CsA act on murine bone marrow DCs, inhibiting IL-2 
production and inducing an immature state and a reduced secretion of Thl cytokines, 
suggesting an additional and potential role of this drug in the generation of transplant 
tolerance (9). 
  
 In this study we focused on the relationship of CsA-modified DC and TREG in order to 
determine the changes that CsA might indirectly produce in these cells following 
antigen presentation. The topic is relevant in the setting of clinical transplantation 
when recipients are treated with anticalcineurinic since day one. 
Accordingly, bone marrow DCs were generated in the presence or absence of CsA and 
then co-cultured with purified Treg cells isolated from TCR transgenic mice. TREG were 
previously labeled with CFSE to analyze their proliferation in the different conditions as 
described. As Fig 1 shows, there is no TREG proliferation in the absence of antigen (OVA 
peptide). In contrast, OVA-pulsed bone marrow DC induced a robust 71,9% TREG 
proliferation (Fig 1A). When CsA was added during DC differentiation, but was absent 
during TREG activation, proliferation reached a value of only 47.7% (a representative 
result out of three experiments). Thus, the fact that DC produced in the presence of 
CsA reduced the proliferation of TREG when compared to DC generated in the absence 
of the drug (Fig 1) demonstrate that CsA, by acting upon the DC is capable of weaken 
TREG proliferative response. 
On the other hand, the presence of CsA during the generation of DC and the period of 
co-culture with TREG (Fig IB) produced an additional reduction of TREG proliferation 
(23.8%), confirming previous data showing that CsA have a direct negative effect on 
TREG. 
In conclusion our findings show that DCs lose an important proportion of their capacity 
to induce TREG proliferation after being generated in the presence of CsA, even though 
an altered phenotype of DC was generated after treatment with the drug, as shown by 
the decrease in MHC expression and CD86 after LPS treatment. The pattern of 
cytokines secreted by DC differentiated with CsA in response to an inflammatory 
stimulus, such as LPS showed a dramatic reduction in IL-2 and IL-12 secretion and an 
increase in IL-10 production. These experiments demonstrate that CsA, through their 
action on DCs precursors impacts negatively on TREG population. These results agree 
with recently published results where the authors compared the capacity of CsA and 
other well-known immunosuppressive drugs on the proliferation and functionality of 
TREG (21) or on the balance TREG/Thl7 (22), both showing a negative impact of CsA on 
TREG function. Further in vitro studies using a wider range of CsA concentrations may 
provide new insights into the complex actions of this drug on DC and TREG proliferation. 
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